ArticleMikrochimica acta2025
A bidirectional immuno-microfluidic chip for detecting autoantibodies based on an indirect assay.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoantibodies play a critical role in predicting diseases and monitoring therapeutic outcomes. Limitations of current autoantibody detection techniques include prolonged detection times and operational complexity. This study aims to develop a bidirectional microfluidic platform for the detection of autoantibodies. A "double inlet" and "waste outlet" structure was developed on the bidirectional lateral-flow microfluidic chip (BiLFMC). Using anti-citrullinated peptide antibodies (ACPA) as a model, this study validated the feasibility and performance advantages of the BiLFMC in the diagnosis of autoimmune disease. The BiLFMC was optimized by selecting the optimal distances between the sample inlet and waste outlet, as well as the ideal diameter for the waste outlet. The most suitable absorbent material was chosen for the waste absorbent pad. The detection and anti-interference performance of the unidirectional mode, unidirectional sequential mode, and bidirectional mode were compared, demonstrating that the bidirectional microfluidic chip significantly enhanced anti-interference capabilities. For ACPA detection, a serum sample required only a 1:100 dilution and 10 μL volume, with results available in 8 min. The coefficient of variation (CV) for repeatability ranged from 7.04% to 13.55%, while the CV for intermediate precision ranged from 11.06% to 14.49%. The limit of quantitation was 3.951 RU/mL, and the upper limit of the linear range was 500 RU/mL. When compared to ELISA results, the consistency coefficient was 0.8302. Furthermore, the BiLFMC was able to accurately distinguish samples exceeding the ELISA upper limit (> 196 RU/mL). A bidirectional microfluidic chip has been developed, incorporating indirect detection methods to enhance the anti-interference capability of the microfluidic platform.
Indexed as
Identifiers
41405727What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.